Global Dry Eye Syndrome Treatment Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dry Eye Syndrome Treatment Sales Market Report 2024
Market Analysis and InsightsGlobal Dry Eye Syndrome Treatment Market
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
Due to the COVID-19 pandemic, the global Dry Eye Syndrome Treatment market size is estimated to be worth US$ 5385 million in 2024 and is forecast to a readjusted size of US$ 7375.6 million by 2034 with a CAGR of 4.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Liquid Drops accounting for % of the Dry Eye Syndrome Treatment global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%.
North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent.
In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
Global Dry Eye Syndrome Treatment Scope and Market Size
The global Dry Eye Syndrome Treatment market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dry Eye Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Liquid Drops
Gel
Liquid Wipes
Eye Ointment
Other
Hospital
Clinic
Home Care
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Novartis
Allergan
Otsuka
Santen Pharmaceutical
Nicox
Auven Therapeutics
Akorn
Bausch & Lomb
Alimera
GlaxoSmithKline
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
Due to the COVID-19 pandemic, the global Dry Eye Syndrome Treatment market size is estimated to be worth US$ 5385 million in 2024 and is forecast to a readjusted size of US$ 7375.6 million by 2034 with a CAGR of 4.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Liquid Drops accounting for % of the Dry Eye Syndrome Treatment global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%.
North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent.
In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
Global Dry Eye Syndrome Treatment Scope and Market Size
The global Dry Eye Syndrome Treatment market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dry Eye Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Liquid Drops
Gel
Liquid Wipes
Eye Ointment
Other
Segment by Application
Hospital
Clinic
Home Care
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Novartis
Allergan
Otsuka
Santen Pharmaceutical
Nicox
Auven Therapeutics
Akorn
Bausch & Lomb
Alimera
GlaxoSmithKline